Accelerated hypofractionated 3-dimensional conformal radiotherapy vs conventional radiotherapy in locally advanced non-small cell lung cancer using PET/CT-derived plan: A prospectively randomized controlled trial

Tumor

Volumn 34, Issue 3, 2014, Pages 253-259

  Yu, Xue Juan ^a   Han, Da Li ^a   Liu, Zeng Jun ^a   Liu, Shan Gang ^a   Zhang, Pin Liang ^a   Li, Ming ^a   Ren, Rui Mei ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Carcinoma, non small cell lung; Chemotherapy; Positron emission tomography; Prognosis; Radiotherapy

Indexed keywords

CISPLATIN; NAVELBINE;

ACCELERATED HYPOFRACTIONATED THREE DIMENSIONAL CONFORMAL RADIOTHERAPY; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ESOPHAGITIS; HUMAN; INDUCTION CHEMOTHERAPY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RADIATION INDUCED ESOPHAGITIS; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE;

EID: 84896944346     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2014.03.009     Document Type: Article

References (13)

1. Ishikura S. Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges[J]. Gen Thorac Cardiovasc Surg, 2012, 60(3):127-131.
2. Eisenhauer EA, Therasseb P, Bogaertsc J, et al. New respongse evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
3. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol, 2004, 22(1):19-22.
4. Mehta M, Scrimger R, Mackie R, et al. A new approach escalation in non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2001, 49(1):23-33.
5. Song DY, Benedict SH, Cardinale RM, et al. Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits[J]. Am J Clin Oncol, 2005(6):591-596.
6. Matsuura K, Kimura T, Kashiwado K, et al. Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer[J]. Int J Clin Oncol, 2009, 14(5):408-415.
7. Kim B, Ahn YC, Lim do H, et al. High-dose thoracic radiation therapy at 3.0 Gy/fraction in inoperable stage ?/? non-small cell lung cancer[J]. Jpn J Clin Oncol, 2008, 38(2):92-98.
8. Kepka L, Tyc-Szczepaniak D, Bujko K. Dose-per-fraction escalation of accelerated hypofractionated three-dimensional conformal radiotherapy in locally advanced non-small cell lung cancer[J]. Thorac Oncol, 2009, 4(7):853-861.
9. Rossier C, Dunet V, Matzinqer O, et al. PET/CT and radiotherapy: indications and potential applications[J]. Cancer Radiother, 2012, 16(2):152-163.
10. Emesto B, Gloria R, Sergio A, et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumor volume and clinical target volume[J]. Eur J Nucl Med Mol Imaging, 2005, 32(12):1392-1399.
11. Nioutsikou E, Partridge M, Bedford JL, et al. Prediction of radiation induced normal tissue comp lications in radiotherapy using functional image data[J]. Phys Med Biol, 2005, 50 (6):1035-1046.
12. Lõcsei Z, Hideghéty K, Farkas R, et al. The use of PET/CT in radiotherapy of patients with non-small cell lung cancer[J]. Magy Onkol, 2011, 55(4):274-280.
13. Vojtísek R, Havránek K, Fínek J. The use of PET/CT fusion in radiotherapy treatment planning of non-small-cell lung cancers[J]. Klin Onkol, 2011, 24(1):23-34.